HBIO · Harvard Bioscience Inc
United States · RS rating 94 · As of 2026-11-03
| Price | 8.67 USD |
|---|---|
| 1-day change | +0.8% |
| RS rating (overall / 1M / 3M / 12M) | 94 / 63 / 93 / 89 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 40 / 77 / 50 |
| Industry group (rank) | Medical-Products (106) |
| EPS growth Q/Q | -100.0% |
| Sales growth Q/Q | +15.3% |
| Distance from 52-week high | +2.6% |
| Market cap (USD) | $30.6M |